Clinical data | |
---|---|
Other names | MK-0434; 17β-Benzoyl-4-aza-5α-androst-1-en-3-one |
Routes of administration | By mouth[1][2] |
Drug class | 5α-Reductase inhibitor |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C25H31NO2 |
Molar mass | 377.528 g·mol−1 |
3D model (JSmol) | |
| |
|
MK-434 is a 5α-reductase inhibitor which was under development in the 1990s by Merck & Co for the treatment of a variety of androgen-dependent conditions including benign prostatic hyperplasia, prostate cancer, pattern hair loss, excessive hair growth, acne, and seborrhea but was never marketed.[1][3][2] It acts as a selective inhibitor of 5α-reductase type 2.[2][3][4] The drug has been found to decrease circulating dihydrotestosterone levels by a maximum of approximately 50% in men.[2][3] MK-434 is a synthetic 4-azasteroid and is structurally related to other 5α-reductase inhibitors like finasteride.[3]